Drug-eluting stents: potential applications for peripheral arterial occlusive disease

J Vasc Interv Radiol. 2003 Mar;14(3):291-301. doi: 10.1097/01.rvi.0000058423.01661.57.

Abstract

Many different approaches have been evaluated to prevent restenosis in stents after vascular implantation. Currently, drug-eluting stents are extremely promising in suppressing neointimal hyperplasia. Various animal studies and randomized trials in humans have shown excellent results in terms of safety and efficacy during intermediate-term follow-up. This article will give an overview of experimental and clinical data of the different agents in published and ongoing trials.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Anti-Inflammatory Agents / administration & dosage
  • Arterial Occlusive Diseases / prevention & control*
  • Coronary Restenosis / prevention & control*
  • Dexamethasone / administration & dosage
  • Drug Delivery Systems
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Paclitaxel / administration & dosage
  • Prosthesis Design
  • Recurrence
  • Sirolimus / administration & dosage
  • Stents*
  • Vascular Patency*

Substances

  • Angiogenesis Inhibitors
  • Anti-Inflammatory Agents
  • Immunosuppressive Agents
  • Dexamethasone
  • Paclitaxel
  • Sirolimus